Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 2/2019

01-02-2019 | Original Article

Desirability of outcome ranking (DOOR) for comparing diagnostic tools and early therapeutic choices in patients with suspected candidemia

Authors: Daniele Roberto Giacobbe, Alessio Signori, Mario Tumbarello, Riccardo Ungaro, Giovanni Sarteschi, Elisa Furfaro, Malgorzata Mikulska, Maurizio Sanguinetti, Brunella Posteraro, Angela Raffaella Losito, Gennaro De Pascale, Valerio Del Bono, Claudio Viscoli

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 2/2019

Login to get access

Abstract

Desirability of outcome ranking (DOOR) has been developed for assessing desirability of outcome in interventional studies. However, its possible use in observational studies of the diagnosis and early treatment of infectious diseases has not been explored so far, and it might introduce interesting features in specific scenarios. This was a post hoc analysis of a prospective observational study in intensive care unit patients with sepsis and at risk of candidemia. The probabilities that a randomly selected patient would have a more, less, and equally cost-effective early therapeutic choice following a BDG-based diagnostic strategy rather than the empirical administration of antifungals to all patients were calculated using DOOR methods. The probability of a more cost-effective therapeutic choice following the BDG-based rather than the empirical strategy was 67.81% (95% CI 67.32–68.30), whereas the probabilities of a less and equally cost-effective early therapeutic choice were 19.68% (95% CI 19.27–20.10) and 12.50% (95% CI 12.16–12.85), respectively. The application of DOOR methods to observational studies focused on diagnosis and early treatment is a novel field that could merit further investigation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Evans SR, Rubin D, Follmann D et al (2015) Desirability of outcome ranking (DOOR) and response adjusted for days of antibiotic risk (RADAR). Clin Infect Dis 61:800–806CrossRefPubMedPubMedCentral Evans SR, Rubin D, Follmann D et al (2015) Desirability of outcome ranking (DOOR) and response adjusted for days of antibiotic risk (RADAR). Clin Infect Dis 61:800–806CrossRefPubMedPubMedCentral
2.
go back to reference Celestin AR, Odom SR, Angelidou K et al (2017) Novel method suggests global superiority of short-duration antibiotics for intra-abdominal infections. Clin Infect Dis 65:1577–1579CrossRefPubMedPubMedCentral Celestin AR, Odom SR, Angelidou K et al (2017) Novel method suggests global superiority of short-duration antibiotics for intra-abdominal infections. Clin Infect Dis 65:1577–1579CrossRefPubMedPubMedCentral
3.
go back to reference Posteraro B, Tumbarello M, De Pascale G et al (2016) (1,3)-b-D-glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study. J Antimicrob Chemother 71:2262–2269CrossRefPubMed Posteraro B, Tumbarello M, De Pascale G et al (2016) (1,3)-b-D-glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study. J Antimicrob Chemother 71:2262–2269CrossRefPubMed
4.
go back to reference Leon C, Ruiz-Santana S, Saavedra P et al (2009) Usefulness of the “Candida score” for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 37:1624–1633CrossRefPubMed Leon C, Ruiz-Santana S, Saavedra P et al (2009) Usefulness of the “Candida score” for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 37:1624–1633CrossRefPubMed
5.
go back to reference Evans S, Follmann D, Schoenfeld D et al (2016) Reply to Phillips, Morris, and Walker. Clin Infect Dis 62:815–816CrossRefPubMed Evans S, Follmann D, Schoenfeld D et al (2016) Reply to Phillips, Morris, and Walker. Clin Infect Dis 62:815–816CrossRefPubMed
6.
go back to reference Phillips PP, Morris TP, Walker AS (2016) DOOR/RADAR: a gateway into the unknown? Clin Infect Dis 62:814–815 Phillips PP, Morris TP, Walker AS (2016) DOOR/RADAR: a gateway into the unknown? Clin Infect Dis 62:814–815
Metadata
Title
Desirability of outcome ranking (DOOR) for comparing diagnostic tools and early therapeutic choices in patients with suspected candidemia
Authors
Daniele Roberto Giacobbe
Alessio Signori
Mario Tumbarello
Riccardo Ungaro
Giovanni Sarteschi
Elisa Furfaro
Malgorzata Mikulska
Maurizio Sanguinetti
Brunella Posteraro
Angela Raffaella Losito
Gennaro De Pascale
Valerio Del Bono
Claudio Viscoli
Publication date
01-02-2019
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 2/2019
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-018-3441-1

Other articles of this Issue 2/2019

European Journal of Clinical Microbiology & Infectious Diseases 2/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.